

Variant: NM_000152.5(GAA):c.853C>T (p.Pro285Ser)

Version: 2.0

CA10603793 [↗](#)

281052 (ClinVar) [↗](#)

Gene: GAA ([HGNC:2548](#))

Condition: glycogen storage disease II ([MONDO:0009290](#))

Inheritance Mode: Autosomal recessive inheritance

UUID: 2a535c11-a37f-4ba1-af92-15a1f7e38989

Approved on: 2026/9/1

Published on: 2026/9/1

HGVS expressions

NM_000152.5(GAA):c.853C>T (p.Pro285Ser)

NM_000152.5:c.853C>T

NC_000017.11:g.80107717C>T

CM000679.2:g.80107717C>T

NC_000017.10:g.78081516C>T

CM000679.1:g.78081516C>T

NC_000017.9:g.75696111C>T

NG_009822.1:g.11162C>T

ENST00000570803.6:c.853C>T

ENST00000572080.2:c.853C>T

ENST00000577106.6:c.853C>T

ENST00000302262.8:c.853C>T

ENST00000302262.7:c.853C>T

ENST00000390015.7:c.853C>T

ENST00000570803.5:c.853C>T

NM_000152.3:c.853C>T

NM_001079803.1:c.853C>T

NM_001079804.1:c.853C>T

NM_000152.4:c.853C>T

NM_001079803.2:c.853C>T

NM_001079804.2:c.853C>T

NM_001079803.3:c.853C>T

NM_001079804.3:c.853C>T

Pathogenic

Met criteria codes 5

PP4_Moderate

PM2_Supporting

PS3_Moderate

PM3_Strong

PP3

Not Met criteria codes 1

PM5

Evidence Links 0

Expert Panel

Lysosomal Diseases VCEP [↗](#)

Criteria Specification Information

[↗](#) **Criteria Specification:** ClinGen Lysosomal Storage Disorders Variant Curation Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 2.0

[↗](#) PDF

[↗](#) Criteria Specification Approval History

Evidence submitted by expert panel

Lysosomal Diseases VCEP

The NM_000152.5:c.853C>T variant in GAA is a missense variant predicted to cause substitution of proline by serine at amino acid 285 (p.Pro285Ser). At least 4 patients with this variant had symptoms consistent with Pompe disease and documented laboratory values showing deficiency GAA activity; one was also treated with ERT (PMID: 21484825, 21550241, 37087815 (PP4_Moderate). All four patients were reported to be compound heterozygous for the variant and another variant in GAA, phase unconfirmed, that has been classified as pathogenic for Pompe disease by the ClinGen LD VCEP. In these cases, the second variant was either c.2560C>T (p.Arg854Ter) (PMID: 37087815; 2 patients, unrelated based on personal communication with author, 2 x 0.5 points), c.1354_1372del19 (PMID: 21550241, 21803581, 0.5 points), c.2237G>A (p.Trp746Ter) (PMID: 21484825, 0.5 points). Total 2 points (PM3_Strong). An infant who was compound heterozygous for the variant and c.670C>T (p.Arg224Trp) was identified on newborn screen but this data will not be included because no further clinical or laboratory data is available (Revvity). The highest population minor allele frequency in gnomAD v4.1.0 is 0.00013 (3/22640 alleles) in the African / African American population which is lower than the ClinGen LD VCEP's threshold (<0.001) for PM2_Supporting, meeting this criterion. The computational predictor REVEL gives a score of 0.757 which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). This variant results in <5% GAA activity when expressed in COS cells, and was classified as Class C ("less severe") by Kroos et al, 2012 (PMID:22644586), meeting the ClinGen LD VCEP criteria for PS3_Supporting. There is a ClinVar entry for this variant (Variation ID: 281052). In summary, this variant meets the criteria to be classified as Pathogenic for Pompe disease based on the GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Storage Disorders Variant Curation Expert Panel (Specifications Version 2.0): PM3_Strong, PP4_moderate, PP3, PM2_supporting, PS3_supporting. (Classification approved by the ClinGen Lysosomal Diseases Variant Curation Expert Panel on September 1, 2026)

Met criteria codes

PP4_Moderate			At least 4 patients with this variant had symptoms consistent with Pompe disease and documented laboratory values showing deficiency GAA activity; one was also treated with ERT (PMID: 21484825, 21550241, 37087815 (PP4_Moderate)).
PM2_Supporting			The highest population minor allele frequency in gnomAD v4.1.0 is 0.00013 (3/22640 alleles) in the African / African American population which is lower than the ClinGen LD VCEP's threshold (<0.001) for PM2_Supporting, meeting this criterion.
PS3_Moderate			This variant results in <5% GAA activity when expressed in COS cells, and was classified as Class C ("less severe") by Kroos et al, 2012 (PMID:22644586), meeting the ClinGen LD VCEP criteria for PS3_Supporting.
PM3_Strong			Four patients with symptoms consistent with Pompe disease and documented laboratory values showing deficiency GAA activity have been reported to be compound heterozygous for the variant and another variant in GAA, phase unconfirmed, that has been classified as pathogenic for Pompe disease by the ClinGen LD VCEP. In these cases, the second variant was either c.2560C>T (p.Arg854Ter) (PMID: 37087815; 2 patients, unrelated based on personal communication with author, 2 x 0.5 points), c.1354_1372del19 (PMID: 21550241, 21803581, 0.5 points), c.2237G>A (p.Trp746Ter) (PMID: 21484825, 0.5 points). Total 2 points (PM3_Strong). An infant who was compound heterozygous for the variant and c.670C>T (p.Arg224Trp) was identified on newborn screen but this data will not be included because no further clinical or laboratory data is available (Revvity).
PP3			The computational predictor REVEL gives a score of 0.757 which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3).

Not Met criteria codes

PM5		
-----	---	---

A different missense change, c.854C>G (p.Pro285Arg) (ClinVarID: 225114), occurs at the same residue and has been classified as likely pathogenic for Pompe disease by the LD VCEP. However, as the classification of p.Pro285Ser was used in the classification of p.Pro285Arg, PM5_Supporting was not applied to avoid circularity.

Curation History [↗](#)



 ▾

 ▾

Showing 1 to 2 of 2 rows

--

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.